Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With COVID-19

NCT04487574 is registered in ClinicalTrials.gov with RSV Therapeutics LLC as lead sponsor.

NCT NCT04487574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04487574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With COVID-19
Lead sponsor
RSV Therapeutics LLC
Phase
Phase 3
Overall status
Completed
Start date
July 25, 2020
Completion date
October 29, 2020
Enrollment
118 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection